You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
PD-1, PD-L1 (B7-H1) and Tumor-Site Immune Modulation Therapy: The Historical Perspective
|
|---|---|
| Published in |
Journal of Hematology & Oncology, January 2017
|
| DOI | 10.1186/s13045-017-0403-5 |
| Pubmed ID | |
| Authors |
Jun Wang, Ruirong Yuan, Wenru Song, Jingwei Sun, Delong Liu, Zihai Li |
| Abstract |
The current success of targeted inhibition against cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and Programmed Death 1/Programmed Death Ligand 1 (PD-1/PD-L1, herein collectively referred to as PD) pathways is hailed as a cancer immunotherapy breakthrough. PD-L1, known also as B7 homolog 1 (B7-H1), was initially discovered by Dr. Lieping Chen in 1999. To recognize the seminal contributions by Chen to the development of PD-directed therapy against cancer, the Chinese American Hematologist and Oncologist Network (CAHON) decided to honor him with its inaugural Lifetime Achievement Award in Hematology and Oncology at the CAHON's 2015 annual meeting. This essay chronicles the important discoveries made by Chen in the exciting field of immuno-oncology, which goes beyond his original fateful finding. It also argues that PD-directed therapy should be appropriately considered as Tumor-Site Immune Modulation Therapy to distinguish it from CTLA-4-based immune checkpoint blocking agents. |
X Demographics
The data shown below were collected from the profiles of 7 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | 29% |
| Denmark | 1 | 14% |
| Unknown | 4 | 57% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 6 | 86% |
| Scientists | 1 | 14% |
Mendeley readers
The data shown below were compiled from readership statistics for 84 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 1% |
| Unknown | 83 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 20 | 24% |
| Student > Bachelor | 12 | 14% |
| Student > Ph. D. Student | 9 | 11% |
| Student > Master | 6 | 7% |
| Other | 4 | 5% |
| Other | 9 | 11% |
| Unknown | 24 | 29% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 13 | 15% |
| Immunology and Microbiology | 13 | 15% |
| Biochemistry, Genetics and Molecular Biology | 12 | 14% |
| Agricultural and Biological Sciences | 8 | 10% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 4% |
| Other | 8 | 10% |
| Unknown | 27 | 32% |
Attention Score in Context
This research output has an Altmetric Attention Score of 15. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 April 2018.
All research outputs
#2,088,402
of 22,968,808 outputs
Outputs from Journal of Hematology & Oncology
#144
of 1,196 outputs
Outputs of similar age
#46,190
of 419,076 outputs
Outputs of similar age from Journal of Hematology & Oncology
#2
of 40 outputs
Altmetric has tracked 22,968,808 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 90th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,196 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.0. This one has done well, scoring higher than 87% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 419,076 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 88% of its contemporaries.
We're also able to compare this research output to 40 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 95% of its contemporaries.